A review of daptomycin for injection (Cubicin) in the treatment of complicated skin and skin structure infections

Therapeutics and Clinical Risk Management

Volumn 2, Issue 2, 2006, Pages 169-174

  Shoemaker, D Matthew ^a   Simou, Jikerkhoun ^a   Roland, William E ^a  

^a UNIVERSITY OF MISSOURI   (United States)

Author keywords

Antibiotic; Daptomycin; Lipopeptide; Skin infection

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; ASPARTATE AMINOTRANSFERASE; BACTERICIDE; CEFTRIAXONE; CIPROFLOXACIN; CLOXACILLIN; CREATINE KINASE; DAPTOMYCIN; FLUCLOXACILLIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPEPTIDE; NAFCILLIN; OXACILLIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRAIN VENTRICULITIS; CLINICAL TRIAL; CONSTIPATION; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG DOSE REGIMEN; DRUG ERUPTION; DRUG EXCRETION; DRUG FEVER; DRUG HALF LIFE; DRUG MECHANISM; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; DYSPNEA; ENDOCARDITIS; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; HEADACHE; HUMAN; HYPERTENSION; HYPOTENSION; INJECTION; INJECTION SITE REACTION; INSOMNIA; KIDNEY FAILURE; KIDNEY FUNCTION; LIMB PAIN; LIVER TOXICITY; MENINGITIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MUSCLE WEAKNESS; MYCOSIS; MYOPATHY; NAUSEA; NONHUMAN; PERITONITIS; PRURITUS; REVIEW; SKIN APPENDAGE DISEASE; SKIN INFECTION; SKIN STRUCTURE; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS DYSGALACTIAE; STREPTOCOCCUS PNEUMONIAE; STREPTOCOCCUS PYOGENES; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VOMITING;

EID: 33745434049     PISSN: 11766336     EISSN: None     Source Type: Journal    
DOI: 10.2147/tcrm.2006.2.2.169     Document Type: Review

References (42)

1. Akins RL, Rybak MJ. 2000. In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model. Antimicrob Agents Chemother, 44:1925-9.
2. Akins RL, Rybak MJ. 2001. Bactericidal activities of two daptomycin regimens against clinical strains of glycopeptide intermediate-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and methicillin-resistant Staphylococcus aureus isolates in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother, 45:454-9.
3. Alborn WE, Allen NE, Preston DA. 1991. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob Agents Chemother, 35:2282-7.
4. Arbeit RD, Maki D, Tally FP, et al 2004. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis, 38:1673-81.
5. Bozdogan B, Esel D, Whitener C, et al. 2003. Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. J Antimicrob Chemother, 52:864-8.
6. Cottagnoud P, Pfister M, Acosta F, et al. 2004. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother, 48:3928-33.
7. Cubicin package insert. 2003. Lexington, MA: Cubist Pharmaceuticals Inc.
8. Dvorchik BH, Brazier D, DeBruin MF, et al. 2003. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother, 47:1318-23.
9. Dvorchik B, Arbeit RD, Chung J, et al 2004. Population pharmacokinetics of daptomycin. Antimicrob Agents Chemother, 48:2799-2807. f
10. Dvorchik B 2004. Moderate liver impairment has no influence on daptomycin pharmacokinetics. J Clin Pharmacol, 44:715-22.
11. Dvorchik DH, Damphousse D. 2005. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol, 45:48-56.
12. Echevarria K, Datta P, Cadena J, et al. 2005. Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother. 55:599-600.
13. Fowler V, Cosgrove S, Abrutyn H, et al. 2005. Daptomycin vs. standard therapy for Staphylococcus aureus bacteremia and infective endocarditis [abstract]. 45th Annual International Conference of Antimicrobial Agents and Chemotherapy, 16-19 December, Washington, DC. USA. K-426a-2005
14. Fuchs PC, Barry AL, Brown SD. 2000. Daptomycin susceptibility tests: interpretive criteria, quality control, and effect of calcium on in vitro tests. Diagn Microbial Infect Dis, 38:51-8.
15. Fuchs PC, Barry AL, Brown SD. 2002. In vitro bactericidal activity of daptomycin against staphylococci. J Antimicrob Chemother, 49:467-70.
16. Haworth CS, Sobieski MW Scheld WM, et al. 1990. Staphylococcus aureus ventriculitis treated with single-dose intraventricular vancomycin or daptomycin (LY146032): bacterial and antibiotic kinetics in hydrocephalic rabbits. Antimicrob Agents Chemother, 34:245-51.
17. Hermsen ED, Hovde LB, Hotchkiss JR, et al. 2003. Increased killing of staphylococci and streptococci by daptomycin compared with cefazolin and vancomycin in an in vitro peritoneal dialysate model. Antimicrob Agents Chemother, 47:3764-7.
18. Jevitt LA, Smith AJ, Williams PP, et al. 2003. In vitro activities of daptomycin, linezolid, and quinupristin-dalfopristin against a challenge panel of staphylococci and enterococci, including vancomycin-intermediate Staphylococcus aureus and vancomycin-resistant Enterococcus faecium. Microbial Drug Resistance, 9:389-93.
19. Levine DP, Lamp KC. 2005. Endocarditis treated with daptomycin; Experience from a registry [abstract]. 43rd IDSA abstracts, Infectious Diseases Society of America, 6-9 October, 2005, San Francisco, CA, USA. 359, p 99.
20. Lipsky BA, Stoutenburgh U. 2005. Daptomycin for treating infected diabetic foot ulcers: evidence from a randomized, controlled trial comparing daptomycin with vancomycin or semi-synthetic penicillins for complicated skin and skin-structure infections. J Antimicrob Chemother, 55:240-5.
21. Long JK, Choueiri TK, Hall GS. et al. 2005. Daptomycin-resistant Enterococcus faecium in a patient with acute myeloid leukemia. Mayo Clinic Proceedings, 80:1215-16.
22. Mangili A, Bica I, Snydman DR et al 2005. Daptomycin-resistant, methicillin-resistant i bacteremia. Clin Infect Dis, 40:1058-0.
23. Mohan SS, McDermott BP, and Cunha BA 2005. Methicillin-resistant Staphylococcus aureus prosthetic aortic valve endocarditis with paravalvular abscess treated with daptomycin. Heart Lung, 34:69-71.
24. Munoz-Price LS, Lolans K, Quinn JP. 2005. Emergence of resistance to daptomycin during treatment of vancomycin-resistant Enterococcus faecalis infection. Clin Infect Dis, 41:565-6.
25. Naber KG, Eisenstein BI, Tally FP. 2004. Daptomycin versus ciprofloxacin in the treatment of complicated urinary tract infection due to gram-positive bacteria. Infect Dis Clin Pract, 12:322-7.
26. Oleson FB, Berman CL, Kirkpatrick JB, et al. 2000. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother, 44:2948-53.
27. Pankuch GA, Jacobs MR, Appelbaum PC. 2003. Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates. Antimicrob Agents Chemother, 47:3012-14.
28. Rao N, David R. 2005. A prospective study evaluating the efficacy of for the treatment of prosthetic joint infections [abstract]. 43rd IDSA abstracts, Infectious Diseases Society of America, 6-9 October, San Francisco, CA, USA. 388, p 105.
29. Richter SS, Kealey DE, Murray CT, et al. 2003. The in vitro activity of daptomycin against Staphylococcus aureus and Enterococcus species. J Antimicrob Chemother, 52:123-7.
30. Sabol K, Patterson JE, Lewis JS, et al. 2005. Emergence of daptomycin resistance in Enterococcus faecium during daptomycin therapy. Antimicrob Agents Chemother, 49:1664-5.
31. Sader HS, Streit JM, Fritsche TR, et al. 2004. Antimicrobial activity of daptomycin against multidrug-resistant gram-positive strains collected worldwide. Diagn Microbiol Infect Dis, 50:201-4.
32. Safdar N, Andes D, Craig WA. 2004. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother, 48:36-8.
33. Silverman JA, Oliver N, Andrew T, et al. 2001. Resistance studies with daptomycin. Antimicrob Agents Chemother, 45:1799-1802.
34. Silverman JA, Mortin LI, Vanpraagh ADC, et al. 2005. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis, 191:2149-52.
35. Steenbergen JN, Alder J, Thorne GM, et al. 2005. Daptomycin: a lipopeptide antibiotic for the treatment of serious Gram-positive infections. J Antimicrob Chemother, 55:283-8.
36. Streit JM, Jones RN, Sader HS. 2004. Daptomycin activity and spectrum: a worldwide sample of 6737 clinical Gram-positive organisms. J Antimicrob Chemother, 53:669-74.
37. Streit JM, Steenbergen JN, Thorne GM, et al. 2005. Daptomycin tested against 915 bloodstream isolates of viridans group streptococci (eight species) and Streptococcus bovis. J Antimicrob Chemother, 55:574-8.
38. Tally FP, DeBruin ME 2000. Development of daptomycin for Gram-positive infections. J Antimicrob Chemother, 46:523-6.
39. Trotman RL, Williamson JC, Shoemaker DM, et al. 2005. Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy. Clin Infect Dis, 41:1159-66.
40. Veligandla SR, Louie KR, Malesker MA, et al. 2004. Muscle pain associated with daptomycin. Ann Pharmacother, 38:1860-2.
41. Wise R, Andrews JM, Ashby JP. 2001. Activity of daptomycin against Gram-positive pathogens: a comparison with other agents and the determination of a tentative breakpoint. J Antimicrob Chemother, 48:563-7.
42. Woodworth JR, Nyhart EH, Brier GL, et al. 1992. Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers. Antimicrob Agents Chemother, 36:318-25.